Skip to main content
GutCited

Lactobacillus rhamnosus GG для Antibiotic-Associated Diarrhea (AAD)

A

Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dlactobacillus\u002Drhamnosus\u002Dgg\u0026condition\u003Dantibiotic\u002Dassociated\u002Ddiarrhea'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Итог

Meta-analyses demonstrate LGG reduces AAD incidence by 42-49%. Most effective when started within 48 hours of antibiotic initiation and continued 7 days after completion.

Key Study Findings

Observational Study n=279
Use of Probiotics During Antibiotic Therapy in Pediatrics: A Cross-Sectional Survey of Italian Primary Care …
Dose: None или: None Outcome: Probiotic prescribing habits of Italian PCPs Эффект: L. rhamnosus GG used by 91.8% None

Популяция: Italian primary care pediatricians

Other
Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and …
Dose: None или: None Outcome: Clinical guideline recommendations for pediatric GI Эффект: None None

Популяция: Pediatric patients with GI disorders

Controlled Clinical Trial n=24 2 weeks
Protective Effect of Probiotics on Cardiac Damage in Experimental Sepsis Model Induced by Lipopolysaccharide in …
Dose: 10^9 CFU/day for 14 days или: LPS-only group (no probiotics) Outcome: Cardiac damage markers (CK-MB, cTn-I, cytokines) Эффект: None p<0.05 to <0.001

Популяция: Male Wistar albino rats with LPS-induced sepsis

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None или: None Outcome: None Эффект: None None

Популяция: Pediatric population

Randomized Controlled Trial Double-blind
A Multi-Hospital Comparative Study on the Efficacy of Probiotics Versus Placebo in Preventing Antibiotic-Associated Diarrhea …
Dose: Probiotics (multi-strain) или: Placebo Outcome: Antibiotic-associated diarrhea incidence Эффект: None None

Популяция: Adult patients receiving antibiotics

Review
Unique Properties of Yeast Probiotic Saccharomyces boulardii CNCM I-745: A Narrative Review.
Dose: S. boulardii CNCM I-745 или: Placebo or standard care Outcome: AAD prevention and pediatric gastroenteritis Эффект: None None

Популяция: AAD and gastroenteritis patients (review)

Key Statistics

20

Исследования

4000

Участники

Positive

A

Оценка

Referenced Papers

Journal of gastroenterology … 2025 10 цитирований
Archivos argentinos de … 2022 23 цитирований
Journal of pediatric … 2016 233 цитирований
Digestive diseases (Basel, … 2016 37 цитирований
Journal of clinical … 2015 35 цитирований
Medycyna wieku rozwojowego 2012 1 цитирований
Current opinion in … 2009 82 цитирований
Advances in biochemical … 2008 535 цитирований
The Journal of … 2007 265 цитирований
The American journal … 2001 648 цитирований

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Часто используемые дозировки

general:
10-20 billion CFU/day
ibssupport:
10 billion CFU/day for 4-8 weeks
aadprevention:
10-20 billion CFU/day (start with antibiotic, continue 7 days after)

Верхний предел: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Дозировки, изученные в исследованиях

Дозировка Длительность Эффект N
None -- Mixed 279
None -- Positive --
10^9 CFU/day for 14 days 2 weeks Positive 24
None -- Mixed --
Probiotics (multi-strain) -- Positive --
S. boulardii CNCM I-745 -- Positive --
None -- Positive --
Twice daily -- Neutral 2650

Лучшее время приёма: On an empty stomach or 30 minutes before meals for optimal survival

Safety & Side Effects

Зарегистрированные побочные эффекты

  • Mild gas and bloating during initial use (usually resolves in 1-2 weeks)
  • Rare reports of bacteremia in severely immunocompromised individuals
  • Occasional loose stools during adjustment period
  • Very rare: systemic infection in critically ill patients with central venous catheters

Известные взаимодействия

  • Antibiotics (may reduce probiotic viability; space dosing 2 hours apart)
  • Immunosuppressants (theoretical risk of infection in immunocompromised patients)
  • Antifungals (no known interaction but may affect gut flora balance)

Допустимый верхний уровень потребления: Generally well-tolerated up to 40 billion CFU/day in clinical trials

Всегда консультируйтесь с врачом перед началом приёма любых добавок.Всегда консультируйтесь с лечащим врачом перед началом приёма любой добавки.

Frequently Asked Questions

Does Lactobacillus rhamnosus GG help with Antibiotic-Associated Diarrhea (AAD)?
Based on 20 studies with 4,000 participants, there is strong evidence from multiple clinical trials that Lactobacillus rhamnosus GG may support Antibiotic-Associated Diarrhea (AAD) management. Our evidence grade is A (Strong Evidence).
How much Lactobacillus rhamnosus GG should I take for Antibiotic-Associated Diarrhea (AAD)?
Studies have used various dosages. A commonly studied range is 10-20 billion CFU/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Lactobacillus rhamnosus GG?
Reported side effects may include Mild gas and bloating during initial use (usually resolves in 1-2 weeks), Rare reports of bacteremia in severely immunocompromised individuals, Occasional loose stools during adjustment period, Very rare: systemic infection in critically ill patients with central venous catheters. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Lactobacillus rhamnosus GG and Antibiotic-Associated Diarrhea (AAD)?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 20 peer-reviewed studies with 4,000 total participants. The overall direction of effect is positive.

Related Evidence

Другие ингредиенты для Antibiotic-Associated Diarrhea (AAD)

Lactobacillus rhamnosus GG для других состояний

Отказ от ответственности FDA: Данные утверждения не были оценены Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов (FDA). Продукты и информация на этом сайте не предназначены для диагностики, лечения, излечения или профилактики каких-либо заболеваний. Представленные оценки доказательности основаны на нашем анализе опубликованных рецензируемых исследований и не являются медицинской консультацией. Всегда консультируйтесь с лечащим врачом перед началом приёма любых добавок.